Dr. Samira Syed, MD, is an Associate Professor of Internal Medicine at UT Southwestern Simmons Comprehensive Cancer Center, where she treats patients and focuses on breast cancer research. In this interview, Dr. Syed discusses recent therapeutic advances and future directions in the treatment of patients with breast cancer. This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the w...
This interview has been conducted in partnership with the National Breast Cancer Foundation (NBCF). Recognized as one of the leading breast cancer organizations in the world, NBCF is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator's highest 4-star rating for 14 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient suppor...
Follicular lymphoma is a disease that affects 2.7 per 100,000 individuals each year, with a five-year survival rate of 89.7%. It is the most common subtype of indolent non-Hodgkin's lymphoma; about 22% of newly diagnosed non-Hodgkin lymphoma cases are follicular lymphoma. The development of novel therapies offers new treatment options for patients living with follicular lymphoma. In this interview, Dr. Loretta J. Nastoupil, MD, Section Chief of New Drug Development in the Department of Lymphoma/...
The FDA has approved amivantamab-vmjw (Rybrevant®, Janssen) for patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. "Despite sharing similar tumor biology to other EGFR-mutant NSCLC tumors, no targeted therapies have been approved for NSCLC harboring EGFR exon 20 insertion mutations," wrote Joshua K. Sabari, MD, medical oncologist at NYU Medical Oncology Associates and colleagues, in the abstract presented in January at the W...
Lung cancer is diagnosed in approximately 235,760 individuals in the United States each year, and 131,880 people die of the disease annually. Non-small cell lung cancer (NSCLC), which accounts for 84% of these cases, has a dismal 5-year survival rate of 18%, and most patients will develop progressive disease within 5 months of their final cycle of first-line classical doublet chemotherapy. The use of tumor histology in determining optimal treatment strategies and relevant molecular biomarkers ha...